• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PTPRK 调节糖酵解和从头脂肪生成以促进肥胖症肝细胞代谢重编程。

PTPRK regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity.

机构信息

Signal Transduction and Metabolism Laboratory, Université libre de Bruxelles, B-1070, Brussels, Belgium.

VIB-VUB Center for Structural Biology, Vlaams Instituut voor Biotechnologie, B-1050, Brussels, Belgium.

出版信息

Nat Commun. 2024 Nov 4;15(1):9522. doi: 10.1038/s41467-024-53733-0.

DOI:10.1038/s41467-024-53733-0
PMID:39496584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11535053/
Abstract

Fat accumulation, de novo lipogenesis, and glycolysis are key drivers of hepatocyte reprogramming and the consequent metabolic dysfunction-associated steatotic liver disease (MASLD). Here we report that obesity leads to dysregulated expression of hepatic protein-tyrosine phosphatases (PTPs). PTPRK was found to be increased in steatotic hepatocytes in both humans and mice, and correlates positively with PPARγ-induced lipogenic signaling. High-fat-fed PTPRK knockout male and female mice have lower weight gain and reduced hepatic fat accumulation. Phosphoproteomic analysis in primary hepatocytes and hepatic metabolomics identified fructose-1,6-bisphosphatase 1 and glycolysis as PTPRK targets in metabolic reprogramming. Mechanistically, PTPRK-induced glycolysis enhances PPARγ and lipogenesis in hepatocytes. Silencing PTPRK in liver cancer cell lines reduces colony-forming capacity and high-fat-fed PTPRK knockout mice exposed to a hepatic carcinogen develop smaller tumours. Our study defines the role of PTPRK in the regulation of hepatic glycolysis, lipid metabolism, and tumour development in obesity.

摘要

脂肪积累、从头合成脂肪和糖酵解是肝细胞重编程和随后的代谢相关脂肪性肝病 (MASLD) 的关键驱动因素。在这里,我们报告肥胖导致肝蛋白酪氨酸磷酸酶 (PTP) 的表达失调。在人和小鼠的脂肪性肝细胞中发现 PTPRK 增加,并且与 PPARγ 诱导的脂肪生成信号呈正相关。高脂肪喂养的 PTPRK 敲除雄性和雌性小鼠体重增加减少,肝脂肪积累减少。在原代肝细胞和肝脏代谢组学中的磷酸蛋白质组学分析鉴定出果糖-1,6-二磷酸酶 1 和糖酵解是代谢重编程中 PTPRK 的靶标。在机制上,PTPRK 诱导的糖酵解增强了肝细胞中的 PPARγ 和脂肪生成。在肝癌细胞系中沉默 PTPRK 会降低集落形成能力,而高脂肪喂养的 PTPRK 敲除小鼠暴露于肝致癌物时会形成较小的肿瘤。我们的研究定义了 PTPRK 在肥胖症中调节肝糖酵解、脂质代谢和肿瘤发生中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/537a989f2e49/41467_2024_53733_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/c24649c1a707/41467_2024_53733_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/bc52c6bd13d5/41467_2024_53733_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/cf9e435e75f8/41467_2024_53733_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/dc19451b0aa9/41467_2024_53733_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/b5867f0c88dd/41467_2024_53733_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/cbde59be673f/41467_2024_53733_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/8dc49bd17072/41467_2024_53733_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/b41f9d5c1dec/41467_2024_53733_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/537a989f2e49/41467_2024_53733_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/c24649c1a707/41467_2024_53733_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/bc52c6bd13d5/41467_2024_53733_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/cf9e435e75f8/41467_2024_53733_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/dc19451b0aa9/41467_2024_53733_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/b5867f0c88dd/41467_2024_53733_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/cbde59be673f/41467_2024_53733_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/8dc49bd17072/41467_2024_53733_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/b41f9d5c1dec/41467_2024_53733_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/602e/11535053/537a989f2e49/41467_2024_53733_Fig9_HTML.jpg

相似文献

1
PTPRK regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity.PTPRK 调节糖酵解和从头脂肪生成以促进肥胖症肝细胞代谢重编程。
Nat Commun. 2024 Nov 4;15(1):9522. doi: 10.1038/s41467-024-53733-0.
2
Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.血小板反应蛋白 1 可改善饮食诱导的胰岛素抵抗小鼠的肝脂肪变性,并且与人类的肝脂肪含量相关。
EBioMedicine. 2020 Jul;57:102849. doi: 10.1016/j.ebiom.2020.102849. Epub 2020 Jun 21.
3
Ghrelin promotes hepatic lipogenesis by activation of mTOR-PPARγ signaling pathway.胃饥饿素通过激活mTOR-PPARγ信号通路促进肝脏脂肪生成。
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13163-8. doi: 10.1073/pnas.1411571111. Epub 2014 Aug 25.
4
Loss of mitogen-activated protein kinase phosphatase-1 protects from hepatic steatosis by repression of cell death-inducing DNA fragmentation factor A (DFFA)-like effector C (CIDEC)/fat-specific protein 27.丝裂原活化蛋白激酶磷酸酶-1 的缺失通过抑制细胞死亡诱导的 DNA 片段化因子 A(DFFA)样效应物 C(CIDEC)/脂肪特异性蛋白 27 来保护肝脏免于脂肪变性。
J Biol Chem. 2011 Jun 24;286(25):22195-202. doi: 10.1074/jbc.M110.210237. Epub 2011 Apr 26.
5
Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice.在成年雄性小鼠中,肝脏PPARγ对于肝脏生长激素信号缺失后脂肪变性的快速发展并非必不可少。
Endocrinology. 2016 May;157(5):1728-35. doi: 10.1210/en.2015-2077. Epub 2016 Mar 7.
6
β-catenin links hepatic metabolic zonation with lipid metabolism and diet-induced obesity in mice.β-连环蛋白将小鼠肝脏代谢分区与脂质代谢及饮食诱导的肥胖联系起来。
Am J Pathol. 2014 Dec;184(12):3284-98. doi: 10.1016/j.ajpath.2014.08.022. Epub 2014 Oct 7.
7
Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARγ.鞘氨醇激酶1缺失改善饮食诱导肥胖小鼠的肝脂肪变性:过氧化物酶体增殖物激活受体γ的作用
Biochim Biophys Acta. 2016 Feb;1861(2):138-147. doi: 10.1016/j.bbalip.2015.11.006. Epub 2015 Nov 23.
8
Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.高脂饮食诱导肥胖和非酒精性脂肪性肝病小鼠肝脏和脂肪组织中调节脂肪生成的转录因子和基因表达改变。
Eur J Gastroenterol Hepatol. 2008 Sep;20(9):843-54. doi: 10.1097/MEG.0b013e3282f9b203.
9
Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.成年小鼠中促进脂肪变性的肝细胞特异性、PPARγ调节机制。
J Endocrinol. 2017 Jan;232(1):107-121. doi: 10.1530/JOE-16-0447. Epub 2016 Oct 31.
10
Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.乙酰辅酶 A 羧化酶 2 基因敲除小鼠在高脂肪、高碳水化合物饮食和从头合成脂肪条件下可防止脂肪肝形成。
J Biol Chem. 2012 Apr 6;287(15):12578-88. doi: 10.1074/jbc.M111.309559. Epub 2012 Feb 23.

引用本文的文献

1
Metabolic dysfunction-associated steatohepatitis reduces hepatic HS-producing enzymes altering persulfidome composition.代谢功能障碍相关脂肪性肝炎会降低肝脏中产生硫化氢的酶,从而改变过硫化蛋白质组的组成。
Redox Biol. 2025 Aug 5;86:103809. doi: 10.1016/j.redox.2025.103809.
2
Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome.解析代谢综合征中饮食诱导的肥胖和糖脂功能障碍的复杂性。
Diabetol Metab Syndr. 2025 Jul 22;17(1):292. doi: 10.1186/s13098-025-01837-y.
3
Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology.

本文引用的文献

1
Protocol for CRISPR-Cas12a genome editing of protein tyrosine phosphatases in human pluripotent stem cells and functional β-like cell generation.CRISPR-Cas12a 基因组编辑人多能干细胞蛋白酪氨酸磷酸酶及功能性β样细胞生成的方案。
STAR Protoc. 2024 Sep 20;5(3):103297. doi: 10.1016/j.xpro.2024.103297. Epub 2024 Sep 6.
2
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.代谢相关脂肪性肝病:新命名对美国肝病研究学会非酒精性脂肪性肝病实践指南的影响及更新。
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
3
蛋白酪氨酸磷酸酶κ型受体(PTPRK)再探讨:对其结构、功能及病理学的新认识
J Transl Med. 2025 May 12;23(1):534. doi: 10.1186/s12967-025-06496-1.
4
Protocol for real-time glycolytic monitoring in mammalian cells using confocal microscopy and HYlight, a biosensor for fructose 1,6-bisphosphate.使用共聚焦显微镜和用于1,6-二磷酸果糖的生物传感器HYlight在哺乳动物细胞中进行实时糖酵解监测的方案。
STAR Protoc. 2025 Apr 23;6(2):103792. doi: 10.1016/j.xpro.2025.103792.
5
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma.代谢功能障碍相关脂肪性肝病(MASLD)相关肝细胞癌的致病机制
Cells. 2025 Mar 13;14(6):428. doi: 10.3390/cells14060428.
Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
致编辑的信:Hepa 1-6可能不适用于肝细胞癌模型以探索对药物治疗的反应。
Hepatology. 2024 Apr 1;79(4):E123-E124. doi: 10.1097/HEP.0000000000000733. Epub 2023 Dec 25.
4
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.回复:关于新的脂肪性肝病命名的多学会德尔菲共识声明。
Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.
5
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.蛋白酪氨酸磷酸酶N2/蛋白酪氨酸磷酸酶N1抑制剂ABBV-CLS-484可释放强大的抗肿瘤免疫力。
Nature. 2023 Oct;622(7984):850-862. doi: 10.1038/s41586-023-06575-7. Epub 2023 Oct 4.
6
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards.单基因炎症性肠病的精准医学:mIBD REPORT 标准建议
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):810-828. doi: 10.1038/s41575-023-00838-4. Epub 2023 Oct 3.
7
Manipulating PTPRD function with ectodomain antibodies.利用外域抗体来操控 PTPRD 功能。
Genes Dev. 2023 Aug 1;37(15-16):743-759. doi: 10.1101/gad.350713.123. Epub 2023 Sep 5.
8
Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma.非酒精性脂肪性肝病和糖尿病作为肝细胞癌日益增多的病因。
JHEP Rep. 2023 Jun 9;5(9):100811. doi: 10.1016/j.jhepr.2023.100811. eCollection 2023 Sep.
9
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.肝细胞癌监测——利用、障碍以及病因变化的影响。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):797-809. doi: 10.1038/s41575-023-00818-8. Epub 2023 Aug 3.
10
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity.小分子抑制剂 PTP1B 和 PTPN2 增强 T 细胞抗肿瘤免疫。
Nat Commun. 2023 Jul 27;14(1):4524. doi: 10.1038/s41467-023-40170-8.